Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats
- 12 March 2013
- journal article
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 49 (3) , 481-491
Abstract
Dipeptidyl peptidase-4 inhibitor (DPP4-I) is clinically used as a new oral antidiabetic agent. Although DPP4 is reportedly associated with the progression of chronic liver diseases, the effect of DPP4-I on liver fibrosis development is still obscure. This study was designed to elucidate the effect of DPP4-I on liver fibrosis development in conjunction with the activated hepatic stellate cells (Ac-HSCs). The antifibrotic effect of DPP4-I was assessed in vivo and in vitro using porcine serum-induced experimental liver fibrosis model. DPP4-I, sitagliptin, at a clinically comparable low dose was administered by gavage daily. DPP4-I significantly attenuated liver fibrosis development along with the suppression of hepatic transforming growth factor (TGF)-β1, total collagen, and tissue inhibitor of metalloproteinases-1 in a dose-dependent manner. These suppressive effects occurred almost concurrently with the attenuation of HSCs activation. Our in vitro studies showed that DPP4-I inhibited platelet-derived growth factor-BB-mediated proliferation of the Ac-HSCs as well as upregulation of TGF-β1 and α1(I)-procollagen at magnitudes similar to those of the in vivo studies. The inhibitory effects of DPP4-I against HSCs proliferation and fibrogenic gene expression are mediated through the inhibition of the phosphorylation of ERK1/2, p38 and Smad2/3, respectively. DPP4-I markedly inhibits liver fibrosis development in rats via suppression of HSCs proliferation and collagen synthesis. These suppressive effects are associated with dephosphorylation of ERK1/2, p38 and Smad2/3 in the HSCs. Since DPP4-I is widely used in clinical practice, this drug may represent a potential new therapeutic strategy against liver fibrosis in the near future.Keywords
This publication has 53 references indexed in Scilit:
- The Role of Metformin in the Management of NAFLDExperimental Diabetes Research, 2011
- Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open- label trialHepatology, 2011
- Therapeutic targets in liver fibrosisAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2011
- Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillariesBiological Chemistry, 2011
- Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 DiabetesDiabetes, 2009
- Mechanisms of Hepatic FibrogenesisGastroenterology, 2008
- AT1 receptor antagonist Candesartan in selected cirrhotic patients: Effect on portal pressure and liver fibrosis markersJournal of Hepatology, 2007
- Emerging insights into Transforming growth factor Smad signal in hepatic fibrogenesisGut, 2007
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003
- Liver fibrosis – from bench to bedsideJournal of Hepatology, 2003